36,909 XNAS Volume
XNAS 31 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Adam K. Stern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2024 | 19,607 | 58,821 (0%) | 0% | 0 | Common Stock | |
| Douglas Jay Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2024 | 19,607 | 68,821 (0%) | 0% | 0 | Common Stock | |
| David Gobel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2024 | 19,607 | 39,214 (0%) | 0% | 0 | Common Stock | |
| Alison Tjosvold Milhous | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2024 | 19,607 | 58,821 (0%) | 0% | 0 | Common Stock | |
| Vaidehi Joshi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2024 | 19,607 | 58,821 (0%) | 0% | 0 | Common Stock | |
| Keith Murphy | Director, EXECUTIVE CHAIRMAN | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 19,607 | 132,641 (0%) | 0% | 0 | Common Stock | |
| Keith Murphy | Director, EXECUTIVE CHAIRMAN | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 574,923 | 574,923 | - | - | Options (right to buy) | |
| Keith Murphy | Director, EXECUTIVE CHAIRMAN | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 143,731 | 143,731 | - | - | Options (right to buy) | |
| Adam K. Stern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2022 | 19,607 | 19,607 (0%) | 0% | 0 | Common Stock | |
| Keith Murphy | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2022 | 19,607 | 93,427 (0%) | 0% | 0 | Common Stock | |
| Douglas Jay Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2022 | 19,607 | 29,607 (0%) | 0% | 0 | Common Stock | |
| David Gobel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2022 | 19,607 | 19,607 (0%) | 0% | 0 | Common Stock | |
| Alison Tjosvold Milhous | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2022 | 19,607 | 19,607 (0%) | 0% | 0 | Common Stock | |
| Vaidehi Joshi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2022 | 19,607 | 19,607 (0%) | 0% | 0 | Common Stock | |
| Keith Murphy | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey N. Miner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Thomas Einar Jurgensen | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| David Gobel | Director | 31 Mar 2022 | 145 | 0 (0%) | 0% | 5.3 | 766 | Common Stock | |
| Vaidehi Joshi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Adam K. Stern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Douglas Jay Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| David Gobel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Alison Tjosvold Milhous | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Jeffrey N. Miner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 52,023 | 52,023 | - | - | Stock Option (Right to Buy) | |
| Jeffrey N. Miner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Jeffrey N. Miner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Thomas Einar Jurgensen | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 52,023 | 52,023 | - | - | Stock Option (Right to Buy) | |
| Douglas Jay Cohen | Director | Purchase of securities on an exchange or from another person at price $ 6.72 per share. | 17 Aug 2021 | 8,750 | 10,000 (0%) | 0% | 6.7 | 58,839 | Common Stock |
| Douglas Jay Cohen | Director | Purchase of securities on an exchange or from another person at price $ 6.72 per share. | 17 Aug 2021 | 1,000 | 1,000 (0%) | 0% | 6.7 | 6,720 | Common Stock |
| Douglas Jay Cohen | Director | Purchase of securities on an exchange or from another person at price $ 6.74 per share. | 17 Aug 2021 | 1,000 | 1,000 (0%) | 0% | 6.7 | 6,738 | Common Stock |
| Keith Murphy | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 20,000 | 66,320 (0%) | 0% | 0 | Common Stock | |
| Keith Murphy | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey N. Miner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Jeffrey N. Miner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Thomas Einar Jurgensen | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Adam K. Stern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Chris Heberlig | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Douglas Jay Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| David Gobel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Alison Tjosvold Milhous | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey N. Miner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Thomas Einar Jurgensen | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.57 per share. | 18 Aug 2020 | 15,700 | 221,743 (0%) | 0% | 0.6 | 8,936 | Common Stock |
| Taylor J. Crouch | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.57 per share. | 18 Aug 2020 | 5,510 | 125,144 (0%) | 0% | 0.6 | 3,136 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.57 per share. | 18 Aug 2020 | 10,900 | 192,758 (0%) | 0% | 0.6 | 6,204 | Common Stock |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.51 per share. | 18 May 2020 | 18,030 | 237,443 (0%) | 0% | 0.5 | 9,253 | Common Stock |
| Taylor J. Crouch | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.51 per share. | 18 May 2020 | 6,340 | 130,654 (0%) | 0% | 0.5 | 3,254 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.51 per share. | 18 May 2020 | 14,630 | 203,658 (0%) | 0% | 0.5 | 7,508 | Common Stock |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.32 per share. | 19 Feb 2020 | 17,100 | 255,473 (0%) | 0% | 0.3 | 5,462 | Common Stock |
| Taylor J. Crouch | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.32 per share. | 19 Feb 2020 | 6,045 | 136,994 (0%) | 0% | 0.3 | 1,931 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.32 per share. | 19 Feb 2020 | 13,850 | 218,288 (0%) | 0% | 0.3 | 4,424 | Common Stock |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.45 per share. | 18 Nov 2019 | 14,410 | 272,573 (0%) | 0% | 0.4 | 6,474 | Common Stock |
| Taylor J. Crouch | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.45 per share. | 18 Nov 2019 | 5,075 | 143,039 (0%) | 0% | 0.4 | 2,280 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.45 per share. | 18 Nov 2019 | 11,695 | 232,138 (0%) | 0% | 0.4 | 5,255 | Common Stock |
| Richard E. Maroun | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2019 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Carolyn D. Beaver | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2019 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Mark Kessel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2019 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Kirk D. Malloy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2019 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| David Shapiro | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2019 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.29 per share. | 16 Aug 2019 | 14,750 | 286,983 (0%) | 0% | 0.3 | 4,213 | Common Stock |
| Taylor J. Crouch | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.29 per share. | 16 Aug 2019 | 5,300 | 148,114 (0%) | 0% | 0.3 | 1,514 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.29 per share. | 16 Aug 2019 | 11,960 | 243,833 (0%) | 0% | 0.3 | 3,416 | Common Stock |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.29 per share. | 16 Aug 2019 | 9,500 | 191,335 (0%) | 0% | 0.3 | 2,713 | Common Stock |
| Steven George Hughes | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.29 per share. | 16 Aug 2019 | 22,230 | 138,484 (0%) | 0% | 0.3 | 6,431 | Common Stock |
| Carolyn D. Beaver | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2019 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Carolyn D. Beaver | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2019 | 30,500 | 30,500 | - | - | Stock Option (Right to Buy) | |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.97 per share. | 16 May 2019 | 15,155 | 301,733 (0%) | 0% | 1.0 | 14,700 | Common Stock |
| Taylor J. Crouch | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.97 per share. | 16 May 2019 | 5,465 | 153,414 (0%) | 0% | 1.0 | 5,301 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.97 per share. | 16 May 2019 | 12,275 | 255,793 (0%) | 0% | 1.0 | 11,907 | Common Stock |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.97 per share. | 16 May 2019 | 9,274 | 200,835 (0%) | 0% | 1.0 | 8,996 | Common Stock |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.07 per share. | 19 Feb 2019 | 16,215 | 316,888 (0%) | 0% | 1.1 | 17,280 | Common Stock |
| Taylor J. Crouch | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.07 per share. | 19 Feb 2019 | 5,665 | 158,879 (0%) | 0% | 1.1 | 6,037 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.07 per share. | 19 Feb 2019 | 13,520 | 268,068 (0%) | 0% | 1.1 | 14,408 | Common Stock |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.07 per share. | 19 Feb 2019 | 10,410 | 210,109 (0%) | 0% | 1.1 | 11,094 | Common Stock |
| David Shapiro | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2018 | 46,500 | 46,500 | - | - | Stock Option (Right to Buy) | |
| David Shapiro | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2018 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.07 per share. | 16 Nov 2018 | 14,720 | 333,103 (0%) | 0% | 1.1 | 15,711 | Common Stock |
| Taylor J. Crouch | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.07 per share. | 16 Nov 2018 | 5,140 | 164,544 (0%) | 0% | 1.1 | 5,486 | Common Stock |
| Sharon Presnell | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.07 per share. | 16 Nov 2018 | 11,200 | 280,993 (0%) | 0% | 1.1 | 11,954 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.07 per share. | 16 Nov 2018 | 11,915 | 281,588 (0%) | 0% | 1.1 | 12,717 | Common Stock |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.07 per share. | 16 Nov 2018 | 9,450 | 220,519 (0%) | 0% | 1.1 | 10,086 | Common Stock |
| Sharon Presnell | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.27 per share. | 08 Nov 2018 | 40,000 | 292,193 (0%) | 0% | 1.3 | 50,800 | Common Stock |
| Craig Kussman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 675,000 | 675,000 | - | - | Stock Option (Right to Buy) | |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.11 per share. | 15 Aug 2018 | 15,320 | 347,823 (0%) | 0% | 1.1 | 16,967 | Common Stock |
| Sharon Presnell | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.11 per share. | 15 Aug 2018 | 11,655 | 332,193 (0%) | 0% | 1.1 | 12,908 | Common Stock |
| Sharon Presnell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 675,000 | 675,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.11 per share. | 15 Aug 2018 | 12,400 | 293,503 (0%) | 0% | 1.1 | 13,733 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 675,000 | 675,000 | - | - | Stock Option (Right to Buy) | |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.11 per share. | 15 Aug 2018 | 9,835 | 229,969 (0%) | 0% | 1.1 | 10,892 | Common Stock |
| Paul Gallant | General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Steven George Hughes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 160,714 | 160,714 (0%) | 0% | 0 | Common Stock | |
| Steven George Hughes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 974,694 | 974,694 | - | - | Stock Option (Right to Buy) | |
| James T. Glover | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2018 | 45,500 | 45,550 | - | - | Stock Option (Right to Buy) | |
| Richard E. Maroun | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2018 | 45,500 | 45,550 | - | - | Stock Option (Right to Buy) | |
| Tamar D. Howson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2018 | 45,500 | 45,550 | - | - | Stock Option (Right to Buy) | |
| Mark Kessel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2018 | 45,500 | 45,550 | - | - | Stock Option (Right to Buy) | |
| Kirk D. Malloy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2018 | 45,500 | 45,550 | - | - | Stock Option (Right to Buy) | |
| Robert Baltera | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2018 | 45,500 | 45,550 | - | - | Stock Option (Right to Buy) | |
| Taylor J. Crouch | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.43 per share. | 22 Jun 2018 | 15,490 | 175,034 (0%) | 0% | 1.4 | 22,194 | Common Stock |
| Taylor J. Crouch | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2018 | 41,764 | 190,524 (0%) | 0% | 0 | Common Stock | |
| Craig Kussman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2018 | 74,380 | 363,143 (0%) | 0% | 0 | Common Stock | |
| Craig Kussman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2018 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Taylor J. Crouch | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2018 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | |
| Taylor J. Crouch | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2018 | 148,760 | 148,760 (0%) | 0% | 0 | Common Stock | |
| Sharon Presnell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2018 | 74,380 | 343,848 (0%) | 0% | 0 | Common Stock | |
| Sharon Presnell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2018 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2018 | 70,248 | 305,903 (0%) | 0% | 0 | Common Stock | |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2018 | 283,333 | 283,333 | - | - | Stock Option (Right to Buy) | |
| Paul Gallant | General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2018 | 266,667 | 266,667 | - | - | Stock Option (Right to Buy) | |
| Paul Gallant | General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2018 | 66,115 | 239,804 (0%) | 0% | 0 | Common Stock | |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.66 per share. | 16 May 2018 | 11,720 | 288,763 (0%) | 0% | 1.7 | 19,480 | Common Stock |
| Sharon Presnell | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.66 per share. | 16 May 2018 | 8,325 | 269,468 (0%) | 0% | 1.7 | 13,837 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.66 per share. | 16 May 2018 | 9,160 | 235,655 (0%) | 0% | 1.7 | 15,225 | Common Stock |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.66 per share. | 16 May 2018 | 6,890 | 173,689 (0%) | 0% | 1.7 | 11,452 | Common Stock |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.09 per share. | 16 Feb 2018 | 13,265 | 300,483 (0%) | 0% | 1.1 | 14,399 | Common Stock |
| Sharon Presnell | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.09 per share. | 16 Feb 2018 | 9,420 | 277,793 (0%) | 0% | 1.1 | 10,225 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.09 per share. | 16 Feb 2018 | 10,365 | 244,815 (0%) | 0% | 1.1 | 11,251 | Common Stock |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.09 per share. | 16 Feb 2018 | 7,820 | 180,579 (0%) | 0% | 1.1 | 8,489 | Common Stock |
| Keith Murphy | Other | Purchase of securities on an exchange or from another person at price $ 1.50 per share. | 22 Nov 2017 | 135,000 | 6,173,173 (5%) | 0% | 1.5 | 201,960 | Common Stock |
| Keith Murphy | Other | Purchase of securities on an exchange or from another person at price $ 1.49 per share. | 22 Nov 2017 | 200,500 | 6,373,673 (5%) | 0% | 1.5 | 299,347 | Common Stock |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.47 per share. | 16 Nov 2017 | 11,890 | 313,748 (0%) | 0% | 1.5 | 17,481 | Common Stock |
| Sharon Presnell | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.47 per share. | 16 Nov 2017 | 5,860 | 287,213 (0%) | 0% | 1.5 | 8,615 | Common Stock |
| Eric David | CSO & EVP Pre-Clinical Dev | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.47 per share. | 16 Nov 2017 | 5,625 | 876,609 (0%) | 0% | 1.5 | 8,270 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.47 per share. | 16 Nov 2017 | 8,900 | 255,180 (0%) | 0% | 1.5 | 13,085 | Common Stock |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.47 per share. | 16 Nov 2017 | 7,015 | 188,399 (0%) | 0% | 1.5 | 10,313 | Common Stock |
| James T. Glover | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2017 | 42,500 | 42,500 | - | - | Stock Option (Right to Buy) | |
| Richard E. Maroun | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2017 | 42,500 | 42,500 | - | - | Stock Option (Right to Buy) | |
| Tamar D. Howson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2017 | 42,500 | 42,500 | - | - | Stock Option (Right to Buy) | |
| Mark Kessel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2017 | 42,500 | 42,500 | - | - | Stock Option (Right to Buy) | |
| Kirk D. Malloy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2017 | 42,500 | 42,500 | - | - | Stock Option (Right to Buy) | |
| Robert Baltera | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2017 | 42,500 | 42,500 | - | - | Stock Option (Right to Buy) | |
| Craig Kussman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.06 per share. | 16 Aug 2017 | 26,362 | 325,638 (0%) | 0% | 2.1 | 54,306 | Common Stock |
| Sharon Presnell | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.06 per share. | 16 Aug 2017 | 6,115 | 293,073 (0%) | 0% | 2.1 | 12,597 | Common Stock |
| Eric David | CSO & EVP Pre-Clinical Dev | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.06 per share. | 16 Aug 2017 | 8,469 | 882,234 (0%) | 0% | 2.1 | 17,446 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.06 per share. | 16 Aug 2017 | 5,871 | 264,080 (0%) | 0% | 2.1 | 12,094 | Common Stock |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.06 per share. | 16 Aug 2017 | 7,324 | 195,414 (0%) | 0% | 2.1 | 15,087 | Common Stock |
| Craig Kussman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2017 | 220,000 | 352,000 (0%) | 0% | 0 | Common Stock | |
| Sharon Presnell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2017 | 200,000 | 299,188 (0%) | 0% | 0 | Common Stock | |
| Eric David | CSO & EVP Pre-Clinical Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2017 | 190,000 | 890,703 (0%) | 0% | 0 | Common Stock | |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2017 | 190,000 | 269,951 (0%) | 0% | 0 | Common Stock | |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2017 | 35,000 | 79,951 (0%) | 0% | 0 | Common Stock | |
| Paul Gallant | General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2017 | 160,000 | 202,738 (0%) | 0% | 0 | Common Stock | |
| Sharon Presnell | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.86 per share. | 16 May 2017 | 1,167 | 99,188 (0%) | 0% | 2.9 | 3,340 | Common Stock |
| Eric David | CSO & EVP Pre-Clinical Dev | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.86 per share. | 16 May 2017 | 1,263 | 700,703 (0%) | 0% | 2.9 | 3,615 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.86 per share. | 16 May 2017 | 1,235 | 44,951 (0%) | 0% | 2.9 | 3,535 | Common Stock |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.86 per share. | 16 May 2017 | 1,317 | 42,738 (0%) | 0% | 2.9 | 3,769 | Common Stock |
| Taylor J. Crouch | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2017 | 2,088,212 | 2,088,212 | - | - | Stock Option (Right to Buy) | |
| Sharon Presnell | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Mar 2017 | 15,000 | 100,355 (0%) | 0% | 0 | Common Stock | |
| Keith Murphy | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Mar 2017 | 19,000 | 6,019,173 (5%) | 0% | 0 | Common Stock | |
| Sharon Presnell | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.95 per share. | 16 Feb 2017 | 1,390 | 115,355 (0%) | 0% | 3.0 | 4,101 | Common Stock |
| Keith Murphy | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.95 per share. | 16 Feb 2017 | 5,742 | 6,038,173 (5%) | 0% | 3.0 | 16,939 | Common Stock |
| Eric David | CSO & EVP Pre-Clinical Dev | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.95 per share. | 16 Feb 2017 | 1,390 | 701,966 (0%) | 0% | 3.0 | 4,101 | Common Stock |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.95 per share. | 16 Feb 2017 | 1,390 | 46,186 (0%) | 0% | 3.0 | 4,101 | Common Stock |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.95 per share. | 16 Feb 2017 | 1,320 | 44,055 (0%) | 0% | 3.0 | 3,894 | Common Stock |
| Keith Murphy | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 3.68 per share. | 08 Feb 2017 | 25,000 | 6,043,915 (5%) | 0% | 3.7 | 92,035 | Common Stock |
| Keith Murphy | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.00 per share. | 08 Feb 2017 | 30,000 | 6,068,915 (5%) | 0% | 1 | 30,000 | Common Stock |
| Keith Murphy | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2017 | 30,000 | 0 | - | - | Warrant | |
| Keith Murphy | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 3.50 per share. | 23 Jan 2017 | 20,100 | 6,038,915 (5%) | 0% | 3.5 | 70,440 | Common Stock |
| Keith Murphy | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 3.51 per share. | 23 Jan 2017 | 4,900 | 6,059,015 (5%) | 0% | 3.5 | 17,215 | Common Stock |
| Keith Murphy | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 14 Dec 2016 | 50,000 | 6,063,915 | - | - | Common Stock | |
| Sharon Presnell | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 16 Nov 2016 | 1,210 | 116,745 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 16 Nov 2016 | 7,200 | 6,113,915 | - | - | Common Stock | |
| Eric David | CSO & EVP Pre-Clinical Dev | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 16 Nov 2016 | 1,745 | 703,356 | - | - | Common Stock | |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 16 Nov 2016 | 1,210 | 47,576 | - | - | Common Stock | |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 16 Nov 2016 | 1,160 | 45,375 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 16 Sep 2016 | 1,394 | 6,121,115 | - | - | Common Stock | |
| Craig Kussman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2016 | 330,000 | 330,000 | - | - | Stock Option (Right to Buy) | |
| Craig Kussman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2016 | 132,000 | 132,000 | - | - | Common Stock | |
| Sharon Presnell | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 19 Aug 2016 | 1,109 | 117,955 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 19 Aug 2016 | 5,129 | 6,122,509 | - | - | Common Stock | |
| Eric David | CSO & EVP Pre-Clinical Dev | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 19 Aug 2016 | 1,205 | 705,101 | - | - | Common Stock | |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 19 Aug 2016 | 1,214 | 48,786 | - | - | Common Stock | |
| Paul Gallant | General Manager | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 19 Aug 2016 | 965 | 46,535 | - | - | Common Stock | |
| Mark Kessel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Mark Kessel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Mark Kessel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 7,500 | 7,500 | - | - | Common Stock | |
| Mark Kessel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 7,500 | 15,000 | - | - | Common Stock | |
| Tamar D. Howson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Tamar D. Howson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 7,500 | 7,500 | - | - | Common Stock | |
| James T. Glover | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| James T. Glover | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 7,500 | 17,500 | - | - | Common Stock | |
| Richard E. Maroun | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Richard E. Maroun | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Richard E. Maroun | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 7,500 | 7,500 | - | - | Common Stock | |
| Richard E. Maroun | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 7,500 | 15,000 | - | - | Common Stock | |
| Kirk D. Malloy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Kirk D. Malloy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 7,500 | 7,500 | - | - | Common Stock | |
| Robert Baltera | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Robert Baltera | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 7,500 | 146,006 | - | - | Common Stock | |
| Taylor J. Crouch | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2016 | 1,350,000 | 1,350,000 | - | - | Stock Option (right to Buy) | |
| Taylor J. Crouch | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 15 Aug 2016 | 5,350 | 169,684 | - | - | Common Stock | |
| Eric David | CSO & EVP Pre-Clinical Dev | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 05 Aug 2016 | 20,000 | 706,306 | - | - | Common Stock | |
| Sharon Presnell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2016 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Sharon Presnell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2016 | 50,000 | 119,064 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2016 | 415,000 | 415,000 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2016 | 208,000 | 6,127,638 | - | - | Common Stock | |
| Eric David | CSO & EVP Pre-Clinical Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2016 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Eric David | CSO & EVP Pre-Clinical Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2016 | 50,000 | 726,306 | - | - | Common Stock | |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2016 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Kinsbruner Bush | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2016 | 50,000 | 50,000 | - | - | Common Stock | |
| Paul Gallant | General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2016 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Paul Gallant | General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2016 | 47,500 | 47,500 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Mar 2016 | 86,808 | 0 | - | - | Common Stock | |
| Eric David | CSO & EVP Pre-Clinical Dev | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Mar 2016 | 5,000 | 676,306 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2016 | 24,690 | 24,690 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 16 Feb 2016 | 24,690 | 5,919,638 | - | - | Common Stock | |
| Robert Baltera | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 21 Sep 2015 | 6,000 | 138,506 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 24 Aug 2015 | 100,692 | 86,808 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2015 | 100,692 | 100,692 | - | - | Stock Option (Right to Buy) | |
| Tamar D. Howson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2015 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| James T. Glover | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2015 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Kirk Malloy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2015 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Robert Baltera | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2015 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Richard A. Heyman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2015 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Paul Gallant | General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2015 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| James T. Glover | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Aug 2015 | 10,000 | 10,000 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Aug 2015 | 20,000 | 5,944,328 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2015 | 255,000 | 255,000 | - | - | Stock Option (Right to Buy) | |
| Sharon Presnell | EVP, Research & Dev & CTO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2015 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2015 | 465,000 | 465,000 | - | - | Stock Option (Right to Buy) | |
| Michael Renard | EVP of Commercial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2015 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Eric David | CSO & EVP Pre-Clinical Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2015 | 130,000 | 130,000 | - | - | Stock Option (Rignt to Buy) | |
| Jennifer Kinsbruner Bush | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2015 | 125,000 | 125,000 | - | - | Stock Option (Rignt to Buy) | |
| Sharon Presnell | EVP, Research & Dev & CTO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Mar 2015 | 5,000 | 69,064 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Mar 2015 | 6,000 | 5,924,328 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Mar 2015 | 31,000 | 5,930,328 | - | - | Common Stock | |
| Sharon Presnell | EVP, Research & Dev & CTO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2015 | 50,000 | 74,064 | - | - | Common Stock | |
| Sharon Presnell | EVP, Research & Dev & CTO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2015 | 50,000 | 622,192 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2015 | 28,008 | 28,008 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 13 Feb 2015 | 28,008 | 5,961,328 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Dec 2014 | 300,646 | 187,500 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 29 Dec 2014 | 4,500 | 296,146 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 29 Dec 2014 | 10,500 | 285,646 | - | - | Common Stock | |
| Eric David | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 29 Dec 2014 | 3,700 | 697,706 | - | - | Common Stock | |
| Eric David | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 29 Dec 2014 | 16,300 | 681,306 | - | - | Common Stock | |
| Malloy Kirk | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2014 | 56,500 | 56,500 | - | - | Stock Option (Right to Buy) | |
| Jennifer Bush | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2014 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Sharon Presnell | EVP, Research & Dev & CTO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 06 Oct 2014 | 50,000 | 24,064 | - | - | Common Stock | |
| Eric David | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 12 Sep 2014 | 30,000 | 701,306 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2014 | 13,157 | 27,343 | - | - | Stock Option (Right to Buy) | |
| Barry D. Michaels | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2014 | 5,317 | 94,683 | - | - | Stock Option (Right to Buy) | |
| Barry D. Michaels | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2014 | 13,157 | 482,829 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2014 | 5,317 | 488,146 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2014 | 102,760 | 102,760 | - | - | Stock Option (Right to Buy) | |
| Barry D. Michaels | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 25 Aug 2014 | 102,760 | 469,672 | - | - | Common Stock | |
| Tamar D. Howson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2014 | 31,500 | 31,500 | - | - | Stock Option (Right to Buy) | |
| James T. Glover | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2014 | 31,500 | 31,500 | - | - | Stock Option (Right to Buy) | |
| Robert Baltera | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2014 | 31,500 | 31,500 | - | - | Stock Option (Right to Buy) | |
| Richard A. Heyman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2014 | 31,500 | 31,500 | - | - | Stock Option (Right to Buy) | |
| Robert Baltera | None | 06 Jun 2014 | 3,000 | 0 | - | - | Warrant (Right to Buy) | ||
| Robert Baltera | None | 06 Jun 2014 | 3,000 | 144,506 | - | - | Common Stock | ||
| Michael Renard | EVP of Commercial Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2014 | 50,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Michael Renard | EVP of Commercial Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2014 | 50,000 | 50,000 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Mar 2014 | 8,000 | 5,989,336 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2014 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Sharon Presnell | EVP, Research & Dev & CTO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2014 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Michael Renard | EVP of Commercial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2014 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Michael Renard | EVP of Commercial Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2014 | 10,000 | 550,000 | - | - | Stock Option (Right to Buy) | |
| Michael Renard | EVP of Commercial Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2014 | 10,000 | 10,000 | - | - | Common Stock | |
| Michael Renard | EVP of Commercial Operations | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 19 Feb 2014 | 10,000 | 0 | - | - | Common Stock | |
| Eric David | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2014 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2014 | 27,307 | 27,307 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2014 | 550,000 | 550,000 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 Feb 2014 | 100,000 | 5,974,643 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2014 | 50,000 | 6,024,643 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 18 Feb 2014 | 27,307 | 5,997,336 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2014 | 22,000 | 40,500 | - | - | Stock Option (Right to Buy) | |
| Barry D. Michaels | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2014 | 22,000 | 572,432 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2014 | 27,105 | 27,105 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 13 Feb 2014 | 27,105 | 6,074,643 | - | - | Common Stock | |
| Michael Renard | EVP of Commercial Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2014 | 10,000 | 590,000 | - | - | Stock Option (Right to Buy) | |
| Michael Renard | EVP of Commercial Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2014 | 30,000 | 560,000 | - | - | Stock Option (Right to Buy) | |
| Michael Renard | EVP of Commercial Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2014 | 10,000 | 10,000 | - | - | Common Stock | |
| Michael Renard | EVP of Commercial Operations | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2014 | 10,000 | 0 | - | - | Common Stock | |
| Michael Renard | EVP of Commercial Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2014 | 30,000 | 30,000 | - | - | Common Stock | |
| Michael Renard | EVP of Commercial Operations | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2014 | 30,000 | 0 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 21 Jan 2014 | 100,000 | 6,101,748 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2013 | 47,619 | 32,068 | - | - | Stock Option (Right to Buy) | |
| Barry D. Michaels | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2013 | 47,619 | 550,432 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Dec 2013 | 85,353 | 502,813 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 10 Dec 2013 | 100,000 | 6,201,748 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 Nov 2013 | 100,000 | 6,301,748 | - | - | Common Stock | |
| Eric David | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 Nov 2013 | 16,470 | 731,306 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Oct 2013 | 30,000 | 6,401,748 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Oct 2013 | 70,000 | 6,431,748 | - | - | Common Stock | |
| Eric David | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 10 Oct 2013 | 3,530 | 747,776 | - | - | Common Stock | |
| Eric David | Chief Strategy Officer | 10 Oct 2013 | 20,000 | 751,306 | - | - | Common Stock | ||
| Eric David | Chief Strategy Officer | 10 Oct 2013 | 20,000 | 0 | - | - | Warrant (Right to Buy) | ||
| Eric David | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Oct 2013 | 63,000 | 731,306 | - | - | Common Stock | |
| Sharon Presnell | EVP, Research & Dev & CTO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 02 Oct 2013 | 75,000 | 74,064 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2013 | 54,654 | 54,654 | - | - | Stock Option (Right to Buy) | |
| Keith Murphy | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 28 Aug 2013 | 54,654 | 6,501,748 | - | - | Common Stock | |
| Keith Murphy | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2013 | 100,000 | 6,556,402 | - | - | Common Stock | |
| Barry D. Michaels | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2012 | 62,500 | 62,500 | - | - | Stock Options (Right to Buy) | |
| Sharon Presnell | EVP, Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2012 | 175,000 | 175,000 | - | - | Stock Options (Right to Buy) | |
| Barry D. Michaels | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Mar 2012 | 10,000 | 10,000 | - | - | Warrants (Right to Buy) | |
| Barry D. Michaels | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Mar 2012 | 10,000 | 10,000 | - | - | Common Stock |